1. Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
    Masaki Terabe et al, 2017, OncoImmunology CrossRef
  2. Targeting the TGFβ pathway for cancer therapy
    Cindy Neuzillet et al, 2015, Pharmacology & Therapeutics CrossRef
  3. Targeting TGF-β Signaling for Therapeutic Gain
    Rosemary J. Akhurst, 2017, Cold Spring Harb Perspect Biol CrossRef
  4. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo
    Xi-Ran He et al, 2017, Journal of Ethnopharmacology CrossRef
  5. Mammary Gland Involution Provides a Unique Model to Study the TGF-β Cancer Paradox
    Qiuchen Guo et al, 2017, JCM CrossRef
  6. Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate
    Aaron Kunamalla et al, 2016, Circ Res CrossRef
  7. Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells
    Peng Wang et al, 2018, Cell Metabolism CrossRef
  8. Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer
    Michiko Harao et al, 2015, BioDrugs CrossRef
  9. Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells.
    Katrin Moses et al, 2016, Semin Immunol CrossRef
  10. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model
    Camila Leonel et al, 2017, J Mammary Gland Biol Neoplasia CrossRef
  11. Reverting Immune Suppression to Enhance Cancer Immunotherapy
    Bella S. Guerrouahen et al, 2020, Front. Oncol. CrossRef
  12. TGFβ biology in cancer progression and immunotherapy.
    Rik Derynck et al, 2021, Nat Rev Clin Oncol CrossRef
  13. null
    Diane Tseng et al, 2020 CrossRef
  14. Recent progress in TGF-β inhibitors for cancer therapy
    Cheng-Yi Huang et al, 2021, Biomedicine & Pharmacotherapy CrossRef
  15. TGFβ signaling networks in ovarian cancer progression and plasticity
    Asha Kumari et al, 2021, Clin Exp Metastasis CrossRef
  16. Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
    Brian T. Welsh et al, 2021, Int J Toxicol CrossRef
  17. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
    Xianhui Chen et al, 2021, Molecular Therapy - Oncolytics CrossRef
  18. null
    Emmanuel Rosas et al, 2021 CrossRef
  19. Overcoming TGFβ-mediated immune evasion in cancer
    Daniele V. F. Tauriello et al, 2021, Nat Rev Cancer CrossRef
  20. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer
    Yun Xing et al, 2022, Acta Pharmacol Sin CrossRef
  21. 3D Printed Scaffold Based on Type I Collagen/PLGA_TGF-β1 Nanoparticles Mimicking the Growth Factor Footprint of Human Bone Tissue
    Federica Banche-Niclot et al, 2022, Polymers CrossRef
  22. Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model
    Masaki Takahashi et al, 2022, Molecular Therapy - Nucleic Acids CrossRef
  23. TGF-β signaling networks in the tumor microenvironment
    Max Kam-Kwan Chan et al, 2022, Cancer Letters CrossRef
  24. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
    Zhen-Hua Wu et al, 2022, Cancers CrossRef
  25. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.
    D Ciardiello et al, 2020, Ann Oncol CrossRef
  26. Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
    Max Kam-Kwan Chan et al, 2023 CrossRef